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 Tetrahydrobiopterin is an essential
cofactor for NO production.
 Limitation of endogenous
tetrahydrobiopterin reduces NO
bioavailability, enhances oxidative stress,
and impairs vascular function.
 Orally supplemented tetrahydrobiopterin
has therapeutic challenges because it is
rapidly oxidized in vivo.
 Here, the authors demonstrate that
L-phenylalanine, when administered orally,
raises vascular tetrahydrobiopterin,
restores NO, reduces superoxide, and
enhances vascular function in
spontaneously hypertensive rats.
 This effect is achieved by activation of a
protein complex (GCH1-GFRP) involved in
the biosynthesis of tetrahydrobiopterin.
 Activation of this protein complex by
L-phenylalanine or its analogues
represents a novel therapeutic target for
vascular disorders underpinned by
reduced NO bioavailability.https://doi.org/10.1016/j.jacbts.2018.01.015
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ABBR EV I A T I ON S
AND ACRONYMS
ACh = acetylcholine
ANOVA = analysis of variance
BH2 = dihydrobiopterin
BH4 = tetrahydrobiopterin
EC50 = effective concentration
for 50% maximal response
EDHF = endothelium derived
hyperpolarizing factor
eNOS = endothelial nitric oxide
synthase
GCH1 = GTP cyclohydrolase-1
GFRP = GCH1 feedback
regulatory protein
L-phe = L-phenylalanine
L-tyr = L-tyrosine
NO = nitric oxide
ROS = reactive oxygen species
SHR = spontaneously
hypertensive rat(s)
WKY = Wistar Kyoto rat(s
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2SUMMARYReduced nitric oxide (NO) bioavailability correlates with impaired cardiovascular function. NO is extremely labile
and has been challenging to develop as a therapeutic agent. However, NO bioavailability could be enhanced by
pharmacologically targeting endogenous NO regulatory pathways. Tetrahydrobiopterin, an essential cofactor
for NO production, is synthesized by GTP cyclohydrolase-1 (GCH1), which complexes with GCH1 feedback
regulatory protein (GFRP). The dietary amino acid L-phenylalanine activates this complex, elevating vascular
BH4. Here, the authors demonstrate that L-phenylalanine administration restores vascular function in a rodent
model of hypertension, suggesting the GCH1-GFRP complex represents a rational therapeutic target for dis-
eases underpinned by endothelial dysfunction. (J Am Coll Cardiol Basic Trans Science 2018;-:-–-) © 2018
The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).C ardiovascular diseases pose aconsiderable societal and economicburden on health care systems (1).
Such diseases are usually associated with
functional and structural changes within
the vascular network as well as concomitant
increases in oxidative stress (2). Endothelial
dysfunction is characterized by impairedvasodilation, mainly due to loss of nitric oxide (NO)
signaling (3,4). NO biosynthesis in the vasculature is
primarily catalyzed by endothelial nitric oxide syn-
thase (eNOS) (5), and tetrahydrobiopterin (BH4) is
an essential cofactor for all 3 isoforms of NOS (6,7).
When BH4 bioavailability is limited, NOS may become
“uncoupled,” producing superoxide at the expense of
NO, thereby potentiating oxidative stress (8). Thus,
raising endothelial BH4 levels has been suggested as
a strategy to maintain healthy NO production and
bioavailability at the level of the endothelium
(9,10). To support this, intra-arterial administration
of BH4 improves endothelial dysfunction in patients
with hypertension (11), coronary artery disease (12),
and hypercholesterolemia (13). However, due to its
unstable nature, orally administered BH4 (or its
analogue sapropterin) has limited efﬁcacy in
improving vascular hemodynamics (14–16). There-
fore, other strategies to raise endogenous BH4
bioavailability at the level of the endothelium are
desirable.
BH4 is synthesized from GTP in a reaction where
the committing step is mediated by GTP
cyclohydrolase-1 (GCH1) (17). Modulation of GCH1
expression has been shown to regulate BH4, NO, and
cardiovascular function (18–20). GCH1 is subject to
feed-forward regulation by L-phenylalanine (L-phe),
via an allosteric protein interaction with GCH1 feed-
back regulatory protein (GFRP) (21,22). This GCH1-
GFRP complex is operative in humans because oral
challenge with L-phe leads to a 3-fold rise in plasma
)biopterin levels (a correlate of BH4)—an effect that is
attenuated in patients with a loss-of-function GCH1
mutation (23). Targeting endogenous BH4 biosyn-
thesis, by activating the GCH1-GFRP axis pharmaco-
logically, thus represents a method to enhance
vascular BH4 levels at the level of the endothelium,
circumventing the poor bioavailability following oral
BH4 administration (14,24).
To support this hypothesis, it is known the GCH1-
GFRP axis regulates BH4 and NO in endothelial cells
(25). Overexpression of GFRP reduces basal BH4 levels
(26) and attenuates the rise in BH4 and NO that occurs
in response to a proinﬂammatory stimulus (27).
Additionally, the primary source of BH4 appears to be
derived from GCH1 localized within the vascular
endothelium, and GFRP is coexpressed within these
cells (28,29). Finally, oral L-phe elicits a rise in
vascular BH4—an effect that is absent in mice lacking
endothelial GCH1 (24).
The GCH1-GFRP axis thus ensures that BH4 levels
are kept within a tight physiological range. However,
the crucial mechanistic link between GCH1-GFRP
activation by L-phe, the concomitant rise in BH4 and
its potential impact on NO and vascular function is
lacking. The aim of this study was to determine
whether L-phe raises vascular BH4 levels by acti-
vating the GCH1-GFRP complex in vivo and improves
endothelial function in an animal model of essential
hypertension.
METHODS
Further details of all assays can be found in the
Supplemental Methods.
EFFECT OF L-PHE ON RECOMBINANTLY EXPRESSED
GCH-1 ACTIVITY. A kinetic microplate assay was used
to determine the effects of L-phe (1 mmol$l1) on the
activity of recombinantly expressed human GCH1
(0.1 mmol$l1) either alone or when coincubated with
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3recombinantly expressed human GFRP (1 mmol$l1)
(24). This assay measures the accumulation of the
intermediate reaction product, dihydroneopterin
triphosphate (H2NTP), by monitoring an increase in
A340 over time (30) (Supplemental Methods).
ANIMALS. Spontaneously hypertensive rats (SHR)
and Wistar Kyoto rats (WKY) were used throughout.
All animal experiments were performed under U.K.
Home Ofﬁce approval according to the Animals
Scientiﬁc Procedures Act, 1986 and subsequent
revisions and conformed to the Guide for the Care and
Use of Laboratory Animals published by the National
Institutes of Health (NIH Publication No. 85-23,
revised 1996). Studies were designed and conducted
in accord with the ARRIVE (Animals in Research:
Reporting In Vivo Experiments) guidelines (31). The
scientiﬁc rational for choice of animal, age group, and
details of experimental design are fully described in
the Supplemental Methods (31).
L-PHE ORAL CHALLENGE: BOLUS DOSING AND
LONG-TERM TREATMENT. A short-term bolus dose of
L-phe (100 mg/kg) or saline control was orally
administered via gavage to 13-week-old WKY or SHR.
Venous blood was collected, under brief inhaled iso-
ﬂurane anesthesia, from the tail of each animal 0.5, 1,
and 4 h after bolus dosing.
For assessment of the long-term effects of L-phe
supplementation, 4-week-old SHR in their pre-
hypertensive stage were given free access to drink-
ing water supplemented with 2.5% w/v L-phe or
saline until they reached 12 weeks of age, after which
plasma and tissue samples were acquired (see the
Supplemental Methods for L-phe dose calculation;
Supplemental Figure 1 for justiﬁcation of the time
course of the long-term L-phe dosing study).
BH4, DIHYDROBIOPTERIN (BH2), AND BIOPTERIN
MEASUREMENT. BH4, BH2, and biopterin were
measured from snap-frozen whole tissue and plasma
using ﬂuorescence and electrochemical detection (32–
34) (see the Supplemental Methods for full details).
NITRITE MEASUREMENT. Quantiﬁcation of total NOx
was performed as previously described using the
modiﬁed Greiss assay (35) and ﬂuorometric detection
(36) (see the Supplemental Methods for full details).
QUANTIFICATION OF SUPEROXIDE LEVELS. Super-
oxide levels were quantiﬁed using a lucigenin
chemiluminescence-based assay as previously
described (37) (see the Supplemental Methods for full
details).
AROMATIC AMINO ACID AND CATECHOLAMINE
MEASUREMENT. Phenylalanine, tyrosine, dopamine,
and adrenaline/noradrenaline were measured byultraviolet spectrophotometric detection in plasma
and tissues (38) (see the Supplemental Methods for
full details).
VASCULAR REACTIVITY OF AORTIC RINGS. Experi-
ments were carried out in fresh rat aortic rings w2
mm in length. Vessels were carefully dissected, and
the endothelium was denuded using a steel wire in a
proportion of rings. All intact and denuded aortic
rings were suspended in an organ bath containing
Krebs buffer, 5 mmol$l1 indomethacin (a cyclo-
oxygenase inhibitor) and gassed with 95% O2 and
5% CO2 at 37C, as previously described (39). The
presence of a functional endothelial cell layer was
conﬁrmed if a clear vasorelaxant response was
observed to 1 mmol$l1 acetylcholine (ACh) in tissues
pre-contracted with 0.1 mmol$l1 phenylephrine.
Endothelium intact vessels that did not display >70%
relaxation to the highest ACh dose were excluded
from the study.
VASCULAR REACTIVITY OF MESENTERIC ARTERIES. Small
resistance arteries (approximately 300 mm, length 3 to
4 mm) were isolated from SHR and WKY mesenteries,
dissected free of surrounding fat and connective tis-
sue, and mounted as isometric preparations on a
Mulvany–Halpern wire myograph (Danish Myo Tech-
nology, Aarhus, Denmark) containing Krebs buffer (as
in the preceding text). As before, the endothelial layer
was intentionally removed in a proportion of the
mesenteric rings. Vessels were stretched to a
circumference 90% of that obtained when subjected
to a transmural pressure of 13.4 kPa (40) before a
routine “run-up” procedure consisting of 4 alternate
contractions to high Kþ solution (as in the preceding
text). Endothelial viability was again assessed by the
addition of 1 mmol$l1 ACh to pre-contracted tissues.
EFFECTS OF SHORT-TERM EXOGENOUS L-PHE ON
THE VASCULAR REACTIVITY OF AORTIC AND
MESENTERIC ARTERIES FROM NAIVE 13-WEEK-OLD
SHR AND WKY. Following the initial vessel setup and
endothelial integrity assessment (described in the
preceding text), all blood vessels were contracted with
effective concentration of phenylephrine for 80%
maximal contraction (EC80) followed by a concentra-
tion response curve to ACh (0.01 to 1 mmol$l1). Tissues
were subsequently washed out and incubated with
0.5 mmol$l1 L-phe or saline control, for 30 min.
Post-incubation, vessels were recontracted with
phenylephrine (EC80), and a second ACh concentration
response curve was constructed. The EC50 values for
ACh were recorded and compared in all vessels, pre-
and post–L-phe incubation. Six aortic and 6mesenteric
rings were acquired from each animal. Three aortic/
mesenteric rings were treated with L-phe, and the
FIGURE 1 Effects of Short-Term L-Phe On Recombinant GCH1 Activity (In Vitro) and Systemic BH4 and Nitrite (In Vivo)
(A) GCH1 activity, determined by the production of the intermediate product reaction; dihydroneopterin triphosphate (DHNTP) at 340 nm of puriﬁed GCH1 (0.1 mmol$l1)
alone or in the presence of puriﬁed GFRP (1 mmol$l1) and/or L-phe (1 mmol$l1). The datasets shown represent the mean  SEM of n ¼ 4 (*p < 0.05). Quantitative
measurement of temporal changes in plasma (B) BH4, and (C) nitrite, (D) BH2, and (E) biopterin following 100 mg$kg1 L-phe challenge in WKY and SHR (given via oral
gavage). The datasets shown represent the mean  SEM of n ¼ 6 animals per group per time point compared with baseline control (0 h) (*p < 0.05, ** p < 0.01,
***p<0.001). (Exact p values are tabulated in the Supplemental Table 2). BH2¼ dihydrobiopterin; BH4¼ tetrahydrobiopterin; eNOS¼ endothelial nitric oxide synthase;
GCH1 ¼ GTP cyclohydrolase 1; L-Arg ¼ L-arginine; L-phe ¼ L-phenylalanine; SHR ¼ spontaneously hypertensive rat(s); WKY ¼Wistar Kyoto rat(s).
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4remaining 3 were controls (saline treated) in each
experiment. Therefore, a total of 6 animals were
used in 6 independent experiments, conducted in
triplicate.
EFFECTSOF LONG-TERMORAL L-PHE SUPPLEMENTATION
ON THE VASCULAR REACTIVITY OF AORTIC AND
MESENTERIC ARTERIES FROM 13-WEEK-OLD SHR. To
assess the effects of long-term L-phe on vascular
reactivity, aortic rings, and mesenteric arteries were
isolated from SHR treated long term with oral L-phe
(8 weeks via drinking water) or saline control, as
described earlier. Aortic and mesenteric rings were
isolated and their integrity assessed as described in
the preceding text. Vessels were pre-contracted with
phenylephrine (EC80), and concentration response
curves to ACh were constructed. The EC50 for ACh
was recorded and compared between L-phe–treated
SHR and compared with vehicle-treated SHR. Six
aortic and 6 mesenteric rings were acquired from each
animal, and a total of 6 animals/group were used in 6
independent experiments in triplicate.Data acqu is i t ion . The changes in tension of all
tissues/rings were measured using a force transducer,
and responses were recorded and analyzed using
LabChart software version 4.2 (ADInstruments
Ltd., Oxford, United Kingdom) by a blinded
investigator.
STATISTICAL ANALYSIS. All data were analyzed us-
ing GraphPad Prism software version 5 (GraphPad
Software, La Jolla, California). Normal distribution of
data was assessed followed by a Student t test or
repeated-measures 1-way analysis of variance
(ANOVA) followed by Bonferroni’s multiple compar-
isons post-test. Two-way ANOVA with Bonferroni
post hoc test was used in the vascular activity ex-
periments where the ANOVA compared the control
(saline-treated) versus L-phe–treated curve for each
experiment. EC50 values were compared using the
Student t test. The following annotation system was
used: *p < 0.05; **p < 0.01; and ***p < 0.001. Exact
p values are listed where feasible in the ﬁgure,
legend, or in the Supplemental Table 2.
FIGURE 2 Effects of Short-Term and Long-Term L-Phe on Tissue BH4 and Nitrite In Vivo
Short-term (100 mg$kg1 L-phe, oral gavage, 4 h, n ¼ 6) and long-term administration (2.5% L-phe in drinking water for 60 days, n ¼ 6) in
SHR on (A) BH4, (B) nitrite, (C) BH2, and (D) biopterin in heart, lung, and liver tissues. The datasets shown represent the mean  SEM where
*p < 0.05, **p < 0.01, and ***p < 0.001. (Exact p values are in the Supplemental Data.) Abbreviations as in Figure 1.
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5RESULTS
EFFECTS OF L-PHE ON RECOMBINANT GCH1
ACTIVITY (IN VITRO) AND SYSTEMIC BH4 AND
NITRITE (IN VIVO). As previously described (24,30),
the combination of puriﬁed recombinant GFRP with
GCH1 protein had a higher basal activity than GCH1
alone in vitro. The addition of L-phe (2 mmol$l1)
had no effect on puriﬁed GCH1 activity alone but
caused a signiﬁcant rise in GCH1 activity when
coincubated with GFRP, conﬁrming that L-phe is an
allosteric regulator of the GCH1-GFRP complex only
(Figure 1A).
In vivo, oral L-phe (100 mg$kg1) bolus to WKY
and SHR signiﬁcantly increased plasma BH4 levels
within 30 min, and levels returned back to baseline
within 4 h (Figure 1B). Correspondingly, a signiﬁcant
rise in nitrite levels was also detected within 30 min,
but whereas this returned to baseline in WKY, it
remained elevated in SHR for at least 4 h (Figure 1C).Interestingly, there were no statistically signiﬁcant
differences in BH2 and biopterin in all groups
although trend increases were observed (Figures 1D
and 1E).
EFFECTS OF BOLUS AND LONG-TERM L-PHE ON
TISSUE BH4 AND NITRITE IN VIVO. Baseline BH4,
BH2, and biopterin levels were measured in plasma,
heart, lung, and liver tissues from 13-week-old SHR
and WKY. BH4, BH2, and/or biopterin were signiﬁ-
cantly reduced in lungs and plasma of SHR compared
with WKY (Figures 2A, 2C, and 2D, Supplemental
Figure 2). L-phe supplementation increased BH4
levels in lung and liver tissues in SHR in the short
term (oral gavage, 4-h time point) and long term
(drinking water, 8 weeks) (Figure 2A).
Nitrite levels were signiﬁcantly lower in the heart,
lung, and liver, but not the plasma, of SHR compared
with WKY (Figure 2B, Supplemental Figure 2). Both
bolus and long-term supplementation of L-phe
normalized nitrite levels in SHR to WKY control
FIGURE 3 Effects of L-Phe on Aortic BH4 and ROS
Effects of L-phe on aortic levels of (A)BH4, (B) superoxide, (C)BH2, and (D)biopterin after short-term (100mg$kg1 L-phe, oral gavage, 4 h) and
long-term administration (2.5% L-phe in drinking water for 60 days, n ¼ 6) in SHR. The datasets shown represent the mean  SEM
where *p< 0.05, **p< 0.01, and ***p< 0.001. Exact p values are in the Supplemental Data. ROS¼ reactive oxygen species; SOD¼ superoxide
dismutase; other abbreviations as in Figure 1.
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6values (Figure 2B). There were no statistically signif-
icant differences in BH2 or biopterin in all groups
following bolus dose and long-term L-phe treatment,
although trend increases were observed (Figures 2C
and 2D, Supplemental Figure 2).
EFFECTS OF L-PHE ON VASCULAR BH4 AND ROS. Further
detailed studies in aortic tissue revealed a signiﬁ-
cantly lower BH4 level in SHR compared with WKY,
which was restored to WKY values following
short-term bolus and long-term L-phe treatment
(Figure 3A). As anticipated, superoxide levels were
higher basally in SHR compared with WKY (Figure 3B).
Bolus dose or long-term administration of L-phe
signiﬁcantly reduced superoxide levels in SHR
(Figure 3B). Superoxide dismutase, the positive con-
trol, reduced superoxide in all study groups
(Figure 3B). Again, we observed no signiﬁcant changes
in BH2 or biopterin in aortic tissue  L-phe adminis-
tration (Figures 3C and 3D). Unfortunately, in aortic
tissues, nitrite levels fell below the limit of detection
and were therefore not quantiﬁable.EFFECTS OF SHORT-TERM L-PHE INCUBATION ON
AORTIC AND MESENTERIC VASCULAR REACTIVITY.
Initial assessment of vascular responses showed that
both the aortic and mesenteric vessels from SHR and
WKY had similar contractile responses to phenyl-
ephrine, whereas endothelial dependent vaso-
relaxation to ACh was diminished in SHR compared
with WKY (Figures 4A and 4C vs. 4B and 4D). Endo-
thelial denudation conferred an 80% to 95% reduc-
tion of Ach-induced vasorelaxation, and there were
no additional effects of L-phe, suggesting that it does
not directly relax the smooth muscle (Figure 4).
Following incubation with 0.5 mmol$l1 L-phe, in the
organ bath, contractile responses to phenylephrine
were unaffected in both SHR and WKY vessels.
Similarly, L-phe incubation had no effect on Ach-
induced vasorelaxation in WKY vessels (Figures 4A
and 4C). However, endothelial dependent relaxation
to ACh was signiﬁcantly improved by L-phe in aorta
and mesenteric vessels from SHR, as reﬂected by the
leftward shift of the dose-response curves (Figures 4B
FIGURE 4 Effects of Short-Term L-Phe on Aortic and Mesenteric Vascular Reactivity
Concentration response curves for acetylcholine in (A) WKY mesenteric rings, (B) SHR mesenteric rings, (C) WKY aortic rings, and (D) SHR
aortic rings, with intact or denuded endothelium following short-term incubation with 0.5 mmol$l1 L-phe. Data represent mean  SEM n ¼
6 animals (in triplicate/animal) for mesenteric arteries and aortic rings (*p < 0.05 and *** p < 0.001 for the whole curve). Table (E) shows
EC50 values (nmol$l
1) comparing saline control with L-phe treatment for each study. Data represent mean EC50 values  SEM, n ¼ 6 in-
dependent experiments (**p < 0.01 and ***p < 0.001). Ach ¼ acetylcholine; EC50 ¼ effective concentration for 50% maximal response;
other abbreviations as in Figure 1.
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7and 4D) and corresponding changes in the EC50 values
(Figure 4C), an effect that was more pronounced in
the mesenteric arteries compared with the aorta.
EFFECTS OF LONG-TERM L-PHE TREATMENT ON
AORTIC AND MESENTERIC VASCULAR REACTIVITY.
Consistent with the effects of short-term L-phe in-
cubation, endothelial-dependent relaxation to ACh in
all vessels from SHR treated long-term with L-phe (8
weeks in drinking water) was signiﬁcantly improved
(p < 0.01) compared with saline control, as reﬂected
by the leftward shift of the dose-response curves and
change in the EC50 values (Figure 5C).
EFFECTS OF BOLUS DOSE AND LONG-TERM L-PHE ON
SYSTEMIC AND TISSUE PHENYLALANINE, TYROSINE,
DOPAMINE, ADRENALINE/NORADRENALINE. L-phe is
metabolized to L-tyrosine (L-tyr) via the action of
phenylalanine hydroxylase in vivo. The ratio ofL-phe/L-tyr was higher in WKY compared with SHR
basally. However, the L-phe/L-tyr ratio was increased
following a bolus dose of L-phe challenge in SHR,
conﬁrming that L-phe was absorbed following oral
gavage (Figure 6A, Supplemental Table 1). We did not
detect a signiﬁcant rise in the L-phe/L-tyr ratio in
animals treated long-term with L-phe. This is not
surprising because the long-term ad libitum L-phe
dosing was at a much lower dose than the short-term
bolus dose challenge. Although there were trends of
decreased dopamine and increased adrenaline/
noradrenaline between SHR and WKY, these did not
reach statistical signiﬁcance in most tissues. The
exception was the heart, where adrenaline/
noradrenaline levels were signiﬁcantly higher in SHR
than WKY basally, but equaled WKY levels following
L-phe treatment (Figures 6B and 6C).
FIGURE 5 Effects of Long-Term L-Phe Treatment on Aortic and Mesenteric Vascular Reactivity
Concentration response curves for acetylcholine in (A) mesenteric arteries and (B) aortic rings isolated from L-phe treated long-term treated
SHR and saline controls. The table (C) shows corresponding EC50 values (*p < 0.05). Data represent mean  SD, n ¼ 6 independent ex-
periments (*p < 0.05 for the whole curve). Abbreviations as in Figures 1 and 4.
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8DISCUSSION
The salient ﬁndings of this work are that oral sup-
plementation of the dietary amino acid L-phe was
able to enhance endogenous BH4 biosynthesis
through the GCH1-GFRP protein complex, elevate
nitrite levels, reduce vascular ROS levels, and
improve endothelium-dependent vascular relaxation.
The functional improvements of L-phe were seen
only in hypertensive animals (SHR), and no change in
functional reactivity was observed in normotensive
(WKY) controls. These beneﬁcial effects were ach-
ieved following both high bolus dose short-term
challenge and following long-term lower-dose ad
libitum supplementation in the drinking water. BH2
and catecholamine levels were not signiﬁcantly
altered by L-phe.
Importantly, this is a proof-of-concept study
demonstrating that GCH1-GFRP is a rational thera-
peutic target for vascular dysfunction. Hence, the
development of L-phe mimetics that selectively bindto and enhance this protein complex may be of clin-
ical value. Our data suggest that L-phe could itself be
translated into the clinic given the minimal effects
observed on catecholamines but should be advanced
with caution, given L-phe’s diverse biological action
and potential for predictable adverse drug reactions.
GCH1 binds to GFRP to form a protein complex that
is receptive to allosteric regulation by both L-phe
(feed forward) and BH4 (feedback) regulation (21). Our
results have conﬁrmed numerous previous reports
that L-phe only enhances GCH1 activity when it is
bound to GFRP (24,30).
In addition to its essential cofactor role for NOS
activation, BH4 is also required by phenylalanine
hydroxylase to catalyze the conversion of L-phe to
L-tyr, which is further converted to dopamine,
adrenaline, and noradrenaline (41). L-phe thus regu-
lates its own metabolism via feed-forward activation
of GCH1-GFRP with subsequent increases in BH4 and
hence phenylalanine hydroxylase activity. This is
important because sustained elevation of L-phe can
FIGURE 6 Effects of Short-Term and Long-Term L-Phe on Systemic and Tissue Phenylalanine, Tyrosine, Dopamine, and Adrenaline/Noradrenaline
Effects of short-term (100 mg$kg1 L-phe, oral gavage, 4 h, n ¼ 6) and long-term administration (2.5% L-phe in drinking water for 60 days, n ¼ 6) in SHR and WKY on
levels of different catecholamines: (A) L-phe/L-tyr ratio, (B) dopamine, and (C) adrenaline/noradrenaline in plasma and tissues. The datasets shown represent the
mean  SEM (n ¼ 6) where *p < 0.05 and **p < 0.01. Abbreviations as in Figure 1.
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9become neurotoxic (42). Indeed, BH4 has been suc-
cessfully used as a treatment for a subset of patients
with phenylketonuria (43). Consistent with raised
biopterin levels seen in patients after L-phe loading
(23) and our previous observations in mice (24),
plasma BH4 levels were signiﬁcantly increased in
control WKY and SHR after 100 mg$kg1 L-phe bolus
oral challenge in the present study.
The SHR is an appropriate model to study endo-
thelial dysfunction because the animals demonstrate
reduced NO signaling, reduced endothelial-
dependent vascular relaxation, enhanced cardiovas-
cular remodeling, and increased oxidative stress
(19,44,45). In this study, lung BH4 levels were lower
in SHR than in age-matched WKY, consistent with
published reports (46). Following a short-term oral
dose (4 h) or long-term daily (8 weeks) L-phe chal-
lenge, tissue BH4 levels in SHR were restored to
control WKY levels.
Correspondingly, we observed increased aortic
superoxide production in SHR basally and L-phe
administration increased aortic BH4 and concomi-
tantly reduced superoxide levels. These data support
the hypothesis that L-phe activates the GCH1-GFRP
complex in vivo, raising endogenous BH4 biosyn-
thesis to support full “coupled” NOS activity, thereby
reducing oxidative stress in this model of
hypertension.
Limited BH4 bioavailability is believed to lead to
NOS uncoupling, generating superoxide instead of
NO (8,47). In SHR, the observed endothelial
dysfunction is, in part, a result of eNOS uncoupling
attributed to BH4 insufﬁciency and NO scavenging by
reactive oxygen species (ROS) (48–50). Interestingly,in this study, L-phe caused a more sustained increase
of plasma nitrite in SHR compared with WKY. This
unexpected, but welcome, observation may be
explained by an exaggerated improvement from a
short-term surge in BH4 in the already compromised
SHR. In other words, the spike in BH4 following L-phe
dosing may have temporarily “recoupled” NOS and
elicited further direct antioxidant effects on other
ROS, thereby greatly enhancing NO and hence nitrite
levels. By contrast, WKY should not have BH4 insuf-
ﬁciency and should have “fully coupled” eNOS.
Hence, the short-term effects of BH4 elevation on
nitrite should be less pronounced. Further mecha-
nistic studies would be required to conﬁrm this
suggestion.
To verify whether L-phe could activate the GCH1-
GFRP axis functionally, a series of studies were car-
ried out using fresh conduit (aortic) and resistance
(mesenteric) blood vessels from WKY and SHR.
Consistent with published reports, Ach-mediated
vascular relaxation in SHR was signiﬁcantly
impaired in comparison to WKY rats. Short-term
L-phe incubation within the organ bath signiﬁcantly
improved vascular relaxation in SHR vessels yet had
no effect on WKY. This implies that L-phe, via local
elevation of BH4 within the vasculature, enhances NO
bioavailability and endothelial function only in cir-
cumstances where the pathway is dysfunctional. This
is consistent with the differential effects on plasma
nitrite between SHR and WKY discussed in the pre-
ceding text. Interestingly, L-phe had a more pro-
nounced effect on vascular relaxation in mesenteric
arteries, suggesting that non-NO–mediated pathways
may have likely been involved as well. Indeed, within
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10this vascular bed, endothelium-derived hyper-
polarizing factor (EDHF) has been proposed to play a
prominent role (51–53). Hydrogen peroxide has been
shown to induce EDHF-like relaxations and promotes
endothelium-dependent and -independent re-
laxations (52,54,55). BH4 can react with molecular
oxygen producing hydrogen peroxide, thereby offer-
ing an additional pathway to promote vascular
relaxation within such resistance vessels (10,56).
Thus, the improved Ach-induced relaxations by L-phe
in mesenteric arteries may have also been mediated
by an improvement of EDHF-like signaling. To rule
out the inﬂuence of prostaglandins on vascular
relaxation, indomethacin was employed throughout
these studies.
BH4 is highly unstable and can be rapidly oxidized
to BH2. Previously, studies have demonstrated that
BH2 can itself bind to the BH4 binding site on NOS but
does not confer any cofactor functionality. Thus,
raised BH2 can be problematic, competing with BH4
for the NOS binding site and promoting NOS uncou-
pling. Importantly, in our study, we did not observe
any signiﬁcant differences in BH2 levels following
L-phe supplementation. This was a surprising ﬁnding
because elevated BH4 is typically associated with a
corresponding rise in BH2. Whether the absence of
BH2 elevation was a consequence of our experimental
design and the time points investigated—or a poten-
tial antioxidant effect of L-phe—remains to be
determined.
It would now be important to establish the in vivo
signiﬁcance of our ﬁndings and to ascertain whether
activation of the GCH1-GFRP axis could attenuate the
development of hypertension in vivo in SHR and in
the clinic. We have previously postulated that L-phe
is not necessarily a viable therapeutic agent in itself,
given its role in catecholamine biosynthesis. Howev-
er, our data revealed no signiﬁcant effects following
both short-term and long-term L-phe challenge on
dopamine, noradrenaline, and adrenaline levels,
indicating that endogenous regulatory mechanisms
may tightly control the bioavailability of these cate-
cholamines. However, our study used L-phe supple-
mentation over a relatively short period of time and
does not reﬂect the projected timeframe for clinical
therapeutics (years). Thus, the observed lack of effect
of L-phe on catecholamine biosynthesis should be
treated with caution and further investigated to fully
understand the impact on non–GCH1-BH4-NO path-
ways. Interestingly, SHR display signiﬁcantly lower
basal L-phe levels compared with WKY; this was not
anticipated and may suggest that the bioavailability
of L-phe may inﬂuence the GCH1-GFRP complex and
hence vascular regulation in these animals.Our study builds upon an existing published re-
ports where numerous attempts to restore NO
bioavailability have been trialed by targeting
different elements of the NOS-NO pathway. These
pathways include substrate enhancement (via L-argi-
nine supplementation), cofactor enhancement (via
BH4 supplementation), or manipulation of the
endogenous NOS inhibitors (asymmetric dimethy-
larginine [ADMA] and L-NMMA) (57). L-Arginine sup-
plementation is by far the most extensively studied,
but results have been variable. Indeed the VINTAGE
MI (Vascular Interaction With Age in Myocardial
Infarction) randomized controlled trial demonstrated
not only lack of efﬁcacy but also higher post-
infarction mortality (58). Further, a meta-analysis of
L-arginine supplementation in myocardial infarction
showed no efﬁcacy (59). Thus, there are efﬁcacy and
safety concerns regarding L-arginine supplementa-
tion in cardiovascular disease patients. The endoge-
nous NOS inhibitor, ADMA competes with L-arginine
for the substrate binding site of NOS, and hence the
efﬁcacy of supplemented L-arginine is dependent
upon the intracellular arginine/ADMA ratio. Finally,
L-arginine has poor oral bioavailability (60), likely
attributable to intestinal arginase activity, and hence
L-citrulline has more recently been suggested as an
alternative method to enhance L-arginine bioavail-
ability (61).
Thus, there is still much work to be undertaken to
improve the efﬁcacy and safety of pharmacotherapies
that enhance NO bioavailability, but our present
study provides the ﬁrst proof-of-concept data that the
GCH1-GFRP complex is a rational therapeutic target to
achieve BH4 elevation and NO restoration within
blood vessels.
To translate these ﬁndings further, we propose 2
parallel research strategies. The ﬁrst clinical devel-
opment strategy would investigate the impact of L-
phe administration on vascular function using ﬂow
mediated dilatation, in patients with existing endo-
thelial dysfunction versus healthy controls. It may be
predicted that ﬂow-mediated dilatation would be
improved in the patient cohort, whereas negligible
effect would be seen in the nonpatient controls.
However, L-phe, as a therapy, may have challenges
given its diverse biological activity, raising potential
safety concerns, and these would need to be
concomitantly investigated in trial participants. The
second parallel strategy would be focused around
drug discovery, to identify small molecules that
selectively bind to and activate the GCH1-GFRP
complex without displaying the dual substrate ac-
tivity for phenylalanine hydroxylase, minimizing the
potential for off-target adverse drug reactions.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: L-phe–mediated GCH1-
GFRP activation leads to a rise in vascular BH4 levels and improved vascular
relaxation in a rodent model of hypertension. Small molecules that mimic this
allosteric activation of GCH1 represent a potential novel therapy to treat a
diverse range of cardiovascular diseases underpinned by limited NO and/or
enhanced oxidative stress.
TRANSLATIONAL OUTLOOK: Our studies demonstrate the mechanism
via which L-phe restores endothelial function in a model of hypertension,
indicating that the GCH1-GFRP complex represents a viable therapeutic
target for the restoration of endothelial function. This method circumvents
the potential oxidative inactivation of BH4 following oral dosing (14).
Although L-phe has been used as a tool to probe the GCH1-GFRP pathway,
it may not be a viable therapeutic agent, given its precursor role for the
biosynthesis of catecholamines. However, small molecules that mimic the
allosteric effects of L-phe at the GCH1-GFRP interface but do not bind to
phenylalanine hydroxylase could be developed, underpinned by endothelial
dysfunction.
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11CONCLUSIONS
Our proof-of-concept study conﬁrms that activation
of GCH1-GFRP can directly affect vascular BH4, NO,
and ROS and restore vascular function in a model of
hypertension. This was achieved using the dietary
amino acid L-phe. It now remains to be determined
whether small-molecule L-phe mimetics require
development or if L-phe itself is a safe and efﬁcacious
treatment for endothelial dysfunction.
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